

Dear Sir/Madam

Thank you for your Freedom of Information request concerning patients have been treated for the following cancers and with the specified drugs.

The Trust can provide the following information:

Therapy	Abiraterone (Zytiga)	Cabazitaxel (Jevtana)	Docetaxel (Taxotere)	Enzalutamide (Xtandi)	Radium-223 (Xofigo)	Others
Patients	nil	nil	nil	nil	nil	nil

If known, how many of the patients treated with Abiraterone, have previously been treated with Docetaxel?

Hepatocellular Carcinoma (HCC) (Primary cancer of the liver)

Therapy	Bevacizumab (Avastin)	Everolimus (Afinitor)	Lapatinib (Tyverb)	Sorafenib (Nexavar)	Sunitinib (Sutent)	Others
Patients	nil	nil	nil	5	nil	nil

Medullary thyroid cancer (MTC) (including multiple endocrine neoplasia type 2 (MEN2) when the carcinoma is within the parathyroid gland and medullary component of the adrenal glands)

Therapy	Axitinib (Inlyta)	Cabozantinib (Cometriq)	Pazopanib (Votrient)	Sunitinib (Sutent)	Vandetanib (Caprelsa)	Others
Patients	nil	nil	nil	nil	nil	nil

Gastrointestinal Stromal Tumours (GISTs) (GISTs including the stomach or small bowel, and anywhere along the length of the digestive tract)

Therapy	Dasatinib (Sprycel)	Imatinib (Glivec)	Nilotinib (Tasigna)	Pazopanib (Votrient)	Regorafenib (Stivarga)	Sorafenib (Nexavar)	Sunitinib (Sutent)	Others
Patients	nil	4	nil	nil	nil	nil	nil	nil

If you have any queries about this response please contact the information governance manager at foi@homerton.nhs.uk, in the first instance. If, following that, you still have any concerns, you may contact the Information Commissioner either by letter, FOI/EIR Complaints resolution, Wycliffe House, Water Lane, Wilmslow, Cheshire SM9 5AF, or by email www.informationcommissioner.gov.uk to take them further.

Incorporating hospital and community health services, teaching and research

Copyright Statement

The material provided is subject to the HUHFT's copyright unless otherwise indicated. Unless expressly indicated on the material to the contrary, it may be reproduced free of charge in any format or medium, provided it is reproduced accurately and not used in a misleading manner. Where any of the copyright items are being re-published or copied to others, you must identify the source of the material and acknowledge the copyright status. Permission to reproduce material does not extend to any material accessed through the Publication Scheme that is the copyright of third parties. You must obtain authorisation to reproduce such material from the copyright holders concerned.

Yours sincerely

James Cook
Information Governance Administrator

James Woollam
Interim -Information Governance Manager